Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial

Radiother Oncol. 2008 May;87(2):221-9. doi: 10.1016/j.radonc.2008.03.008. Epub 2008 Apr 12.

Abstract

Background and purpose: The aim of the study was to define the added value of whole body FDG-PET in screening for distant metastases in patients with head and neck squamous cell carcinoma and risk factors.

Materials and methods: In a multi-center prospective study between 1998 and 2003, 145 consecutive HNSCC patients with risk factors for distant metastases underwent chest CT and whole body FDG-PET for screening of distant metastases. The data of 92 evaluable patients who developed distant metastases or who had a follow-up of at least 12 months were analyzed. Besides their performance in clinical practice, the operational characteristics of PET and CT using ROC analyses were investigated.

Results: Pretreatment screening identified distant metastases in 19 patients (21%). FDG-PET had a higher sensitivity (53% vs. 37%) and positive predictive value (80% vs. 75%) than CT. The combination of CT and FDG-PET had the highest sensitivity (63%). The ROC analyses of the five point ordinal scales revealed that the "area under the curve" (AUC) of FDG-PET was significantly higher as compared to CT.

Conclusion: In HNSCC patients with risk factors, pretreatment screening for distant metastases by chest CT is improved by FDG-PET.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / diagnostic imaging
  • Carcinoma, Squamous Cell / pathology*
  • Female
  • Fluorodeoxyglucose F18*
  • Head and Neck Neoplasms / diagnostic imaging
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis / diagnostic imaging*
  • Prospective Studies
  • ROC Curve
  • Radiography, Thoracic
  • Radiopharmaceuticals*
  • Risk Factors
  • Sensitivity and Specificity
  • Tomography, Emission-Computed / methods*
  • Tomography, X-Ray Computed / methods*
  • Whole Body Imaging

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18